Phase II study of NGR-hTNF in combination with doxorubicin in relapsed ovarian cancer patients

BACKGROUND: The NGR-hTNF (asparagine–glycine–arginine–human tumour necrosis factor) is able to promote antitumour immune responses and to improve the intratumoural doxorubicin uptake by selectively damaging tumour blood vessels. METHODS: Patients progressing after ⩾1 platinum/taxane-based regimen re...

Cijeli opis

Spremljeno u:
Bibliografski detalji
Glavni autori: Lorusso, D, Scambia, G, Amadio, G, di Legge, A, Pietragalla, A, De Vincenzo, R, Masciullo, V, Di Stefano, M, Mangili, G, Citterio, G, Mantori, M, Lambiase, A, Bordignon, C
Format: Artigo
Jezik:Inglês
Izdano: Nature Publishing Group 2012
Teme:
Translational Therapeutics
Online pristup:https://ncbi.nlm.nih.gov/pmc/articles/PMC3389423/
https://ncbi.nlm.nih.gov/pubmed/22644293
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/bjc.2012.233
Oznake: Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!

Similar Items